Oncocyte (IMDX) vs. Its Competitors Head to Head Review

Oncocyte (NASDAQ:IMDX) is one of 860 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Oncocyte to similar businesses based on the strength of its valuation, risk, earnings, profitability, dividends, institutional ownership and analyst recommendations.

Profitability

This table compares Oncocyte and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncocyte	-2,955.63%	N/A	-107.52%
Oncocyte Competitors	-9,425.07%	-127.38%	-33.07%

Earnings & Valuation

This table compares Oncocyte and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Oncocyte	$4.05 million	-$50.22 million	-2.69
Oncocyte Competitors	$688.97 million	$9.83 million	-11.81

Oncocyte’s competitors have higher revenue and earnings than Oncocyte. Oncocyte is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Oncocyte and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncocyte	1	0	2	0	2.33
Oncocyte Competitors	9357	14863	44502	1505	2.54

Oncocyte presently has a consensus target price of $10.50, suggesting a potential upside of 161.85%. As a group, “Biotechnology” companies have a potential upside of 56.86%. Given Oncocyte’s higher possible upside, equities research analysts clearly believe Oncocyte is more favorable than its competitors.

Insider & Institutional Ownership

55.3% of Oncocyte shares are owned by institutional investors. Comparatively, 48.0% of shares of all “Biotechnology” companies are owned by institutional investors. 2.2% of Oncocyte shares are owned by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Oncocyte has a beta of 1.8, suggesting that its share price is 80% more volatile than the S&P 500. Comparatively, Oncocyte’s competitors have a beta of 1.25, suggesting that their average share price is 25% more volatile than the S&P 500.

Summary

Oncocyte beats its competitors on 7 of the 13 factors compared.

Oncocyte Company Profile

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.